Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9409741 | 0.80 | GSK3B (0.70) | GSK3BPTPN1 | |
| SCHEMBL16110122 | 0.77 | PTPN1 (0.61) | GSK3BPTPN1AKR1C3AKR1C2 | |
| SCHEMBL1169066 | 0.77 | AKR1C3 (0.72) | AKR1C3AKR1C2PTGS1PTGS2TAS2R14 | |
| SCHEMBL29520207 | 0.76 | CES2 (0.61) | GSK3BPTPN1 | |
| SCHEMBL167913 | 0.76 | CES2 (0.61) | GSK3BPTPN1 | |
| SCHEMBL29495930 | 0.76 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS1PTGS2TAS2R14 | |
| SCHEMBL477610 | 0.76 | AKR1C3 (0.51) | AKR1C3AKR1C2KDM1APTGS1PTGS2 | |
| SCHEMBL1195462 | 0.76 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS1PTGS2TAS2R14 | |
| SCHEMBL30782680 | 0.75 | ALDH1A1 (0.58) | AKR1C3AKR1C2PTGS1PTGS2TAS2R14 | |
| SCHEMBL1194011 | 0.75 | GSK3B (0.46) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | F2R, TFPI, F2RL1 | GSK3B 3927/4885PTPN1 729/4885AKR1C3 1437/4885 |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | GSK3B 2612/4885PTPN1 1291/4885AKR1C3 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.